Lyell Immunopharma, Inc.
LYEL
$8.69
-$0.89-9.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 133.33% | -15.38% | 36.00% | -51.85% | -95.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 133.33% | -15.38% | 36.00% | -51.85% | -95.38% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 133.33% | -15.38% | 36.00% | -51.85% | -95.38% |
| SG&A Expenses | 4.09% | 10.29% | -24.11% | -35.60% | -30.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -27.60% | -33.30% | -150.00% | -71.53% | 14.21% |
| Total Operating Expenses | 0.94% | 4.52% | -14.43% | -21.83% | -11.27% |
| Operating Income | -0.93% | -4.52% | 14.45% | 21.81% | 11.18% |
| Income Before Tax | 13.96% | -262.62% | 12.33% | 28.30% | 9.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.96% | -262.62% | 12.33% | 28.30% | 9.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.96% | -262.62% | 12.33% | 28.30% | 9.40% |
| EBIT | -0.93% | -4.52% | 14.45% | 21.81% | 11.18% |
| EBITDA | -4.15% | -5.00% | 15.04% | 23.37% | 12.16% |
| EPS Basic | 25.86% | -227.41% | 14.04% | 29.76% | 11.06% |
| Normalized Basic EPS | 10.84% | 3.16% | 14.23% | 28.63% | 15.23% |
| EPS Diluted | 25.86% | -227.41% | 14.04% | 29.76% | 11.06% |
| Normalized Diluted EPS | 10.84% | 3.16% | 14.23% | 28.63% | 15.23% |
| Average Basic Shares Outstanding | 16.07% | 10.74% | 1.99% | 2.08% | 1.87% |
| Average Diluted Shares Outstanding | 16.07% | 10.74% | 1.99% | 2.08% | 1.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |